Gain Therapeutics (GANX) Gains from Investment Securities (2020 - 2025)
Historic Gains from Investment Securities for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to -$10864.0.
- Gain Therapeutics' Gains from Investment Securities fell 12458.86% to -$10864.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 million, marking a year-over-year decrease of 34676.52%. This contributed to the annual value of $3.2 million for FY2024, which is 2245.84% up from last year.
- According to the latest figures from Q3 2025, Gain Therapeutics' Gains from Investment Securities is -$10864.0, which was down 12458.86% from -$673289.0 recorded in Q2 2025.
- Over the past 5 years, Gain Therapeutics' Gains from Investment Securities peaked at $2.6 million during Q2 2023, and registered a low of -$673289.0 during Q2 2025.
- Over the past 5 years, Gain Therapeutics' median Gains from Investment Securities value was $166132.0 (recorded in 2024), while the average stood at $594004.0.
- In the last 5 years, Gain Therapeutics' Gains from Investment Securities crashed by 145150.56% in 2021 and then soared by 1517815.29% in 2022.
- Gain Therapeutics' Gains from Investment Securities (Quarter) stood at -$403938.0 in 2021, then skyrocketed by 188.93% to $359212.0 in 2022, then plummeted by 62.22% to $135697.0 in 2023, then plummeted by 508.25% to -$553984.0 in 2024, then soared by 98.04% to -$10864.0 in 2025.
- Its Gains from Investment Securities was -$10864.0 in Q3 2025, compared to -$673289.0 in Q2 2025 and -$109591.0 in Q1 2025.